Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 45Lymphoma, Mantle-Cell 22Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell 10Leukemia 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Neoplasms 4Hodgkin Disease 4Leukemia, Prolymphocytic 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Chromosome 17 deletion 3Burkitt Lymphoma 3Bronchiolitis Obliterans Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1

Interventions

fludarabine phosphate 3midostaurin 2Whole-Body Irradiation 2Therapeutics 2Mycophenolic Acid 2Methotrexate 2Cyclosporine 2Busulfan 2thymoglobulin 1ibrutinib 1hydrocortisone valerate 1fludarabine 1denileukin diftitox 1avapritinib 1Thiotepa 1Tacrolimus 1Sunitinib 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Leucovorin 1Imatinib Mesylate 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Granisetron 1Filgrastim 1Epoetin Alfa 1Enzyme-Linked Immunosorbent Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Mast-Cell × ibrutinib × Clear all
NCT02415608 2018-09-20

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Stanford University

Phase 2 Terminated
4 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡